Business · 20/11/20261 min read
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000256717
Summary
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000256717